Based in Laval, Canada, Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic areas of eye-health, gastroenterology (GI), and dermatology.

The company restructured its business and sold the units that were not performing well.

The company conducts its business in four operating segments:

•    The Bausch + Lomb/International segment consists of sales of pharmaceutical products in The United States, OTC products and medical device products, primarily comprised of Bausch + Lomb products, with a focus on the vision care, surgical, consumer and ophthalmology Rx products. The segment generated 55% of total revenues in 2020.
 
•    The Salix segment consists of sales in the U.S. of gastrointestinal products. The segment generated 23.7% of total revenues in 2020.
 
•    The Ortho Dermatologics segment consists of: sales Ortho Dermatologics in the United States (dermatological) products and (ii) global sales of Solta medical dermatological devices. The segment generated 6.8% of total revenues in 2020.
 
•    The Diversified Products segment consists of sales of pharmaceutical products in the areas of neurology and certain other therapeutic classes in the United States, generic products, and dentistry products. The segment generated 14.5% of total revenues in 2020.

In August 2020, Bausch announced that it intends to separate its eye-health business into an independent, publicly-traded entity from the remainder of Bausch Health Companies Inc. The separation will establish two separate companies that include: (i) a fully integrated eye-health company, which will consist of the Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmology Rx businesses and (ii) a diversified pharmaceutical company, which will include the Salix, International Rx, Solta, generic products, neurology, dentistry and medical dermatology pharmaceutical businesses.


Revenues came in at $8 billion in 2020, down 7% from 2019.